The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Gamzatov T.H.

Sokolov’s Hospital №122 of the Federal Medical and Biological Agency

Svetlikov A.V.

L.G. Sokolov Clinical Hospital №122, FMBA of Russia;
I.I. Mechnikov North-West State Medical University, St. Petersburg, Russia

The modern principles of management of intermittent claudication

Authors:

Gamzatov T.H., Svetlikov A.V.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2016;(12): 77‑87

Read: 37183 times


To cite this article:

Gamzatov TH, Svetlikov AV. The modern principles of management of intermittent claudication. Pirogov Russian Journal of Surgery. 2016;(12):77‑87. (In Russ.)
https://doi.org/10.17116/hirurgia20161277-87

Recommended articles:
Predictors of myocardial infa­rction in patients with stable peri­pheral artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):61-65
Features of care of patients with cardiovascular diseases and cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):99-104

References:

  1. Fowkes F, Rudan D, Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet. 2013;382(9901):1329-1340. doi: 10.1016/s0140-6736(13)61249-0
  2. National guidelines on the management of patients with peripheral arterial disease. Russian consensus document of Russian Society of Angiology and Vascular Surgery, the Association of Cardiovascular Surgeons of Russia, Russian Society of endovascular surgeons and interventional radiologists , Russian Scientific Society of Cardiology , Phlebology Association . M. 2013. (In Russ.). Accessed August 31, 2016 Available at: http://www.angiolsurgery.org/recommendations/2013/recommendations_LLA.pdf
  3. Hirsch A. Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. JAMA. 2001;286(11):1317. doi: 10.1001/jama.286.11.1317
  4. Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery. 2007;45(1):5-67. doi: 10.1016/j.jvs.2006.12.037
  5. Nehler M, Duval S, Diao L et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. Journal of Vascular Surgery. 2014;60(3):686-695.e2. doi: 10.1016/j.jvs.2014.03.290
  6. JONASON TRINGQVIST I. Factors of Prognostic Importance for Subsequent Rest Pain in Patients with Intermittent Claudication. Acta Medica Scandinavica. 2009;218(1):27-33. doi: 10.1111/j.0954-6820.1985.tb08820.x
  7. Komarov A, Panchenko E, Deev A, Davletov K, Eshkeeva A, Markova L, Karpov Y. The flow of intermittent claudication and prognosis of patients with atherosclerotic lesions of arteries of the lower extremities . Analysis of the results of a prospective follow-up. Angiologiya i sosudistaya khirurgiya. 2000;6:2:9-18. (In Russ.).
  8. SCANDINAVIANSIMVASTATINSURVIVAL. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934). doi: 10.1016/s0140-6736(94)90566-5
  9. Mohler E. Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease. Circulation. 2003;108(12):1481-1486. doi: 10.1161/01.cir.0000090686.57897.f5
  10. Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. The American Journal of Medicine. 2003;114(5):359-364. doi: 10.1016/s0002-9343(03)00010-x
  11. Collaboration A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi: 10.1136/bmj.324.7329.71
  12. Hirsch A, Haskal Z, Hertzer N et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Journal of the American College of Cardiology. 2006;47(6):1-192. doi: 10.1016/j.jacc.2006.02.024
  13. Radack K. ß-Adrenergic Blocker Therapy Does Not Worsen Intermittent Claudication in Subjects With Peripheral Arterial Disease. Arch Intern Med. 1991;151(9):1769. doi: 10.1001/archinte.1991.00400090063012
  14. Ahimastos A, Walker P, Askew C et al. Effect of Ramipril on Walking Times and Quality of Life Among Patients With Peripheral Artery Disease and Intermittent Claudication. JAMA. 2013;309(5). doi: 10.1001/jama.2012.216237
  15. Conte M, Pomposelli F, Clair D et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. Journal of Vascular Surgery. 2015;61(3):2-41.e1. doi: 10.1016/j.jvs.2014.12.009
  16. Robless P, Mikhailidis D, Stansby G. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews. 2007. doi: 10.1002/14651858.cd003748.pub2
  17. De Backer T, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ. 2009;338(mar10 1):603-603. doi: 10.1136/bmj.b603
  18. de Backer T, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews. 2012. doi: 10.1002/14651858.cd001368.pub4
  19. de Backer T, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews. 2008. doi: 10.1002/14651858.cd000988.pub3
  20. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews. 2001. doi: 10.1002/14651858.CD003159
  21. Elwan O, Helmy A, Tamawy M et al. Ergoloids and ischaemic strokes; efficacy and mechanism of action. Journal International Medical Reserch. 1995;23(3):154-166.
  22. Winblad B, Fioravanti M, Dolezal T et al. Therapeutic Use of Nicergoline. Clinical Drug Investigation. 2008;28(9):533-552. doi: 10.2165/00044011-200828090-00001
  23. Meilhac B, Montestruc F, Aubin F, Djian F, Rouffy J. Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication. Therapie. 1997;52(3):179-186.
  24. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels J. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews. 2012. doi: 10.1002/14651858.cd005262.pub2
  25. Dawson D, Cutler B, Hiatt W et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American Journal of Medicine. 2000;109(7):523-530. doi: 10.1016/s0002-9343(00)00569-6
  26. Virgolini I, Fitscha P, Linet O, O'Grady J, Sinzinger H. A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease. Prostaglandins. 1990;39(6):657-664. doi: 10.1016/0090-6980(90)90025-q
  27. Diehm C, Balzer K, Bisler H et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: Results of a multicenter placebo-controlled double-blind trial.Journal of Vascular Surgery. 1997;25(3):537-544. doi: 10.1016/s0741-5214(97)70265-9
  28. Momsen A, Jensen M, Norager C, Madsen M, Vestersgaard-Andersen T, Lindholt J. Drug Therapy for Improving Walking Distance in Intermittent Claudication: A Systematic Review and Meta-analysis of Robust Randomised Controlled Studies. European Journal of Vascular and Endovascular Surgery. 2009;38(4):463-474. doi: 10.1016/j.ejvs.2009.06.002
  29. Reiter M, Bucek R, Stümpflen A, Minar E. Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews. 2003. doi: 10.1002/14651858.cd000986.pub2
  30. Kovalenko V.I. et al. The possibilities of treatment of patients with atherosclerotic lesions of arteries of the lower extremities. Vrach. 2010;3:1-3. (In Russ.).
  31. Gaddi A, et al. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. Journal International Medical Reserch. 1996;24:389-406.
  32. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database of Systematic Reviews. 2001. doi: 10.1002/14651858.cd001999
  33. Buchmayer F, Pleiner J, Elmlinger M, Lauer G, Nell G, Sitte H. Actovegin®: a biological drug for more than 5 decades. Wiener Medizinische Wochenschrift. 2011;161(3-4):80-88. doi: 10.1007/s10354-011-0865-y
  34. Fedorovich A. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvascular Research. 2012;84(1):86-93. doi: 10.1016/j.mvr.2012.03.011
  35. Shval'b P, Gavrilenko A, Kalinin R et al. Efficacy and safety of novaskulgen drug in the treatment of patients with chronic lower limb ischemia (Phase 2b — 3 clinical trials). Kletochnaya transplantologiya i tkanevaya inzheneriya, 2011;6(3):76-83. (In Russ.).
  36. Chervyakov Yu, Staroverov I, Nersesyan E et al. Therapeutic angiogenesis in the treatment of patients with chronic obliterating diseases of lower limb arteries . Immediate and long-term results. Angiologiya i sosudistaya khirurgiya. 2012;18(3):19-27. (In Russ.).
  37. Rutherford R, Baker J, Ernst C et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. Journal of Vascular Surgery. 1997;26(3):517-538. doi: 10.1016/s0741-5214(97)70045-4
  38. McDaniel M, Macdonald P, Haver R, Littenberg B. Published Results of Surgery for Aortoiliac Occlusive Disease. Annals of Vascular Surgery. 1997;11(4):425-441. doi: 10.1007/s100169900073
  39. Klein W, van der Graaf Y, Seegers J, Moll F, Mali W. Long-term Cardiovascular Morbidity, Mortality, and Reintervention after Endovascular Treatment in Patients with Iliac Artery Disease: The Dutch Iliac Stent Trial Study. Radiology. 2004;232(2):491-498. doi: 10.1148/radiol.2322030725
  40. Leville C, Kashyap V, Clair D et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. Journal of Vascular Surgery. 2006;43(1):32-39. doi: 10.1016/j.jvs.2005.09.034
  41. Bradbury A, Adam D, Bell J et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. Journal of Vascular Surgery. 2010;51(5):5-17. doi: 10.1016/j.jvs.2010.01.073
  42. Jack L. Cronenwet, K. Wayne Johnston: Rutherford's Vascular Surgery, 8th ed. Saunders; 2014;1721.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.